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Abstract
RNA interference (RNAi) is a set of intracellular pathways in eukaryotes that controls both exogenous and endogenous gene
expression. The power of RNAi to knock down (silence) any gene of interest by the introduction of synthetic small-
interfering (si)RNAs has afforded powerful insight into biological function through reverse genetic approaches and has
borne a new field of gene therapeutics. A number of questions are outstanding concerning the potency of siRNAs,
necessitating an understanding of how short double-stranded RNAs are processed by the cell. Recent work suggests
unmodified siRNAs are protected in the intracellular environment, although the mechanism of protection still remains
unclear. We have developed a set of doubly-fluorophore labeled RNAs (more precisely, RNA/DNA chimeras) to probe in real-
time the stability of siRNAs and related molecules by fluorescence resonance energy transfer (FRET). We find that these RNA
probes are substrates for relevant cellular degradative processes, including the RNase H1 mediated degradation of an DNA/
RNA hybrid and Dicer-mediated cleavage of a 24-nucleotide (per strand) double-stranded RNA. In addition, we find that 21-
and 24-nucleotide double-stranded RNAs are relatively protected in human cytosolic cell extract, but less so in blood serum,
whereas an 18-nucleotide double-stranded RNA is less protected in both fluids. These results suggest that RNAi effector
RNAs are specifically protected in the cellular environment and may provide an explanation for recent results showing that
unmodified siRNAs in cells persist intact for extended periods of time.
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Introduction
RNA interference (RNAi), first described in the nematode C.
elegans [1], is a set of conserved post-transcriptional gene silencing
pathways in eukaryotes. Following the first demonstration that
RNAi is functional in human cells and receptive to using synthetic
small interfering (si)RNA effector molecules [2], significant
progress has been made in harnessing the RNAi pathway for
functional genomics and for therapies targeting previously
‘‘undruggable’’ genetic targets [3–6]. Inside the cell, double-
stranded siRNAs specifically interact with a number of proteins
including the endoribonuclease Dicer that cleaves them from long
precursor RNAs and steers incorporation of this product into a
multiprotein complex referred to as the RNA-induced silencing
complex (RISC). One strand of the siRNA duplex is retained in
RISC and acts as a template for the sequence-specific identifica-
tion and site-specific cleavage of messenger (m)RNAs and
concomitant reduction in gene expression.
The inherent sensitivity of RNA molecules both inside and
outside the cell towards degradation by ribonucleases motivated an
immediate focus on development of chemically modified siRNAs
that can withstand nucleolytic extracellular environments and reach
the cellular milieu intact [3]. Investigations into the determinants of
siRNA stability have focused on extracellular stability, intracellular
stability, and potency of silencing. First, to mimic the extracellular
environment several groups have used blood serum and purified
nucleases to determine the sensitivity of siRNAs to degradation.
Chemical modifications were found to impart a considerable degree
of nuclease resistance to siRNAs whileretaining the abilityto induce
silencing through the RNAi pathway [7–18]. Furthermore,
chemical modifications were found to be absolutely essential for
systemic delivery of siRNA, both to mediate binding to serum
proteins to increase circulating half-life and to block sites vulnerable
to nuclease attack [14,15]. Only few exceptions to this tendency
towards RNA-hostile extracellular environments exist [19].
The intracellular milieu, which is the functional environment of
the siRNA, is the second environment to which the siRNA is
exposed. By monitoring the expression of a target gene, several
groups were able to assess the potency and duration of siRNA
effects, including a number of studies that focused on determining
whether chemically modified siRNAs are more potent than
unmodified siRNAs [7–11,13,16]. A recent study has shown,
however, that enhanced intracellular nucleolytic stability is not
necessarily correlated with increased duration of the silencing
effect [8]. In fact, the authors found that silencing in non-dividing
cells persisted for up to one month from a single dose of an
unmodified siRNA, suggesting that siRNAs may be quite stable
inside the cell.
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stability and localization by introducing fluorophore modified
siRNAs into live cells and using various microscopy techniques
[20]. siRNAs are actively exported from the nucleus [21], except
in cases where the RNA target is located in the nucleus [22].
Fluorescence fluctuation spectroscopy has been utilized in a
separate study to assess the integrity of labeled intracellular RNAs,
revealing that doubly-labeled RNA suitable for fluorescence
resonance energy transfer (FRET) measurement between the
fluorophores is relatively unstable in single-stranded form
compared to the corresponding siRNA duplex [23]. Intracellular
FRET imaging of dsRNAs has also been employed to show that
intact siRNA duplexes accumulate in cellular foci identified as P-
bodies [24,25]. We have used FRET labeled single-stranded
RNAs to show that secondary structure in general attenuates
degradation in human cell extracts [26].
The precise origin of the apparent intracellular protection of
siRNAs is unclear. Long duration of silencing in non-dividing cells
may be indicative of the stability of the single-stranded guide
strand incorporated into RISC. Prior to RISC maturation, it can
be assumed that some stability is derived from the decreased
nuclease sensitivity of double-stranded RNA compared to single-
stranded RNA [23,26]. Previous intracellular fluorescence studies
[21–25] have focused, however, only on canonical 21–22
nucleotide (nt, per strand) siRNAs, while the observation that
the RNAi pathway can utilize 21- to 27-nt double-stranded RNAs
[27] suggests that intracellular double-stranded RNAs are
discriminated based on length.
To better evaluate the potential of siRNAs in gene therapeutics,
a real-time characterization of their degradation kinetics under
extracellular and intracellular conditions is necessary. Such an
assay should include rapid and precise assessment of RNA stability
as a function of bodily fluid, base paring partner, and RNA size
and should eventually be amenable to high-throughput screening
for optimizing siRNA drugs. To this end, we here have developed
a generalizable series of RNAs modified for FRET measurements,
where two uridines in positions 7 and 16 of the 21-nt guide strand
were replaced with amino-modified deoxythymidines to introduce
two fluorophores that undergo distance dependent FRET
(Figure 1). We varied the size of the labeled strand to generate
double-stranded (ds)RNAs ranging from 18–24 nt per strand
(while keeping the fluorophore distance constant, Figure 1). We
find that our dsRNA probes interact with enzymes in RNAi-active
cytosolic extract from human HeLa cells, including RNase H1 (21-
nt DNA/RNA hybrid) and Dicer (24-nt dsRNA). The DNA/RNA
hybrid degradation by RNase H1 is quite efficient, with observed
rate constants exceeding those for the single-stranded RNA, which
is not expected to be an RNase H1 substrate. Furthermore, our
experimental design allows us to correlate the previously studied
potency/size relationships for siRNAs [27,28] with a real-time
readout of RNA stability. Our results demonstrate that 21- and 24-
nt dsRNAs are protected in cell extract relative to the 18-nt
dsRNA, potentially contributing to the longevity of intracellular
RNAi effects.
Results
We here have developed a set of fluorescein (FL) and
tetramethylrhodamine (TMR) modified RNAs (or, more precisely,
RNA-DNA chimeras with two 29-deoxy modifications necessary
for fluorophore labeling; Figure 1) for use in studies of
intracellular and extracellular RNA stability by real-time FRET.
To specifically address the question of how double-stranded RNAs
are recognized as substrates by intra- and extracellular ribonucle-
ases, we developed three dsRNAs (Figure 1) of 18, 21, and 24 nt
length that bracket the canonical human siRNA length and are
derived from an siRNA previously developed and validated
against the pp-luc luciferase gene [12,28]. We fluorophore labeled
the strand that dominantly acts as guide for the RNAi machinery
and is antisense to the luciferase mRNA [12,28]. We first sought to
compare the degradation of these dsRNAs with those of the
corresponding, relatively unstructured single-stranded RNA
(ssRNA, Figure 1) and its hybrid with a fully complementary
DNA under our standard conditions of near-physiologic buffer
(50 mM Tris-HOAc, pH 7.4, 80 mM KCl, 20 mM NaCl, and
1 mM MgCl2)a t3 7 uC.
Double-stranded RNA is stabilized in both cell extract
and serum
To establish the relative degradation of a 21-nt dsRNA
compared to a DNA/RNA hybrid and ssRNA, we applied our
steady-state FRET assay to compare the degradation of these
complexes upon the addition of 30% (v/v) of either fetal bovine
serum (FBS) or HeLa S100 cytosolic cell extract, equivalent to
11.1 mg/ml total serum and 2.49 mg/ml total cellular protein,
respectively. The blood serum contains a significant fraction of
RNase A-like enzymes [29], whereas the cell extract contains the
protein components of the RNAi pathway and was previously
tested as RNAi-active [12].
In general, a decrease in FRET ratio should be indicative of
degradation of the labeled strand, as cleavage between the
fluorophore labels is expected to lead to a decrease in FRET
efficiency. Surprisingly, when the dsRNAs were incubated in
serum, we observed two fast phases representing increases in
FRET ratio, followed by a slow decrease (Figure 2A). Assays
using purified RNase A (the major type of ribonuclease present in
serum) qualitatively reproduced this shape of the FRET ratio time
trace (Figure S1). In cell extract, the fast phase(s) decreased
significantly (Figure 2E). To assess which phase and correspond-
ing rate constant from the FRET traces reflect RNA degradation,
we used 59-
32P radiolabeling of the 21-nt fluorophore-modified
guide strand and denaturing gel electrophoretic analysis [12] to
determine the degradation rate constant independent of the real-
time output of our FRET trace (Figures 2B,F). Gels were
quantified for the fraction of the guide strand that was intact,
therefore quantifying only primary cleavage events. The resulting
data were plotted and fit with exponential functions (double-
exponential increase for serum and single-exponential decrease for
HeLa cell extract). Comparison with these data unambiguously
identifies the relevant degradation rate constants from the FRET
time traces as the dominant rise phases in serum and the dominant
decrease phase in HeLa cell extract (Figures 2A,E). We note that
the curvatures and rates of the radioactively monitored decay time
courses are well reflected in the real-time FRET time traces
(despite the fact that the FRET trace in serum is inverted),
attesting to the validity of using FRET to monitor the integrity of
the guide strand over time. The increase in FRET particularly
upon degradation in serum may be due to, for example, transient
formation of doubly-labeled, (partially) single-stranded RNAs with
shorter fluorophore distances.
We next qualitatively showed by denaturing FRET gel analysis
that serum manifests more efficient cleavage of the ssRNA
compared to either the DNA/RNA or the dsRNA duplex
(Figure 2C). While the cleavage patterns of the DNA/RNA
hybrid and dsRNA are quite similar, the cleavage pattern of the
ssRNA is notably different. These differences include accumula-
tion of a slight TMR-only band in the ssRNA sample (note the
similar color to the reference TMR-only control lane), which
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also significant accumulation of intermediate size (5–13 nt)
products that are either singly TMR or FL labeled. By contrast,
products smaller than 5 nt are almost absent from the ssRNA
lanes, suggesting primarily endonucleolytic, rather than 59
exonucleolytic, decay (and/or very rapid degradation of smaller
fragments). Some accumulation of short FL-only labeled products
is seen upon degradation of the DNA/RNA hybrid and dsRNA,
suggesting limited 59 exonuclease activity.
The degradation patterns in HeLa cell extract are markedly
different (Figure 2G). Most notably, the DNA/RNA hybrid is
more completely degraded in HeLa cell extract, whereas the
ssRNA is more completely degraded in serum (compare with
Figure 2C). Another difference between serum and cell extract is
the significant accumulation of short (,5 nt) products in the HeLa
lanes, suggesting that these samples contain substantial detectable
59 and 39 exonucleolytic activities. The gel also shows that
degradation of ssRNA by HeLa cell extract generates long (15–
20 nt) exonucleolytic products that are not found for either the
DNA/RNA hybrid or dsRNA (Figure 2G). There is also a FL-
only labeled, somewhat diffuse band found in all samples
incubated with cell extract that co-migrates with an ,15-nt
RNA fragment (Figure 2G). Given that the two fluorophores are
attached only 8 nt apart (Figure 1) this band may be evidence of
a tight interaction of a component of the cell extract with a shorter,
FL-only labeled fragment, leading to a band shift in the denaturing
gel.
Applying our real-time FRET degradation assay to the three
fluorophore labeled RNA variants allowed us to determine their
decay rate constants over a range of total protein concentrations
from added serum or cell extract (Figures 2 D,H). Consistent
with our qualitative observations by gel electrophoresis, the fastest
observed rate constants are found for the decay of ssRNA in serum
(maximum velocity at saturation, vmax=2.7 min
21; half-titration
point FBS1/2=0.14 mg/ml; Figure 2D). Degradation rate
constants are significantly slower upon formation of secondary
structure, as the dsRNA (vmax=0.47 min
21; FBS1/2=7.7 mg/ml)
and particularly the DNA/RNA hybrid (vmax=0.03 min
21;
FBS1/2=0.46 mg/ml) are less efficiently degraded.
The relative decay kinetics in HeLa cell extract (Figure 2H) are
significantly different from those in serum (compare with
Figure 2D). Here the DNA/RNA hybrid is most efficiently
degraded (vmax=7.4 min
21; HeLa1/2=7.6 mg/ml; Figure 2H),
while the ssRNA is relatively protected (vmax=0.60 min
21;
HeLa1/2=1.9 mg/ml). We find that the secondary structured
dsRNA is most strongly protected in cell extract, leading to only a
slow decay (vmax=0.02 min
21; HeLa1/2=0.18 mg/ml). In both
cell extract and blood serum, the formation of dsRNA thus
protects ssRNA against nucleolytic degradation.
DNA/RNA hybrid is degraded by RNase H1 in HeLa cell
extract
One of the most prominent features of our decay data is the fast
degradation of the DNA/RNA hybrid in HeLa S100 cytosolic cell
extract, contrasting with its strong protection in blood serum. We
hypothesized that the efficient degradation of the DNA/RNA
hybrid in cell extract results from the activity of human RNase H
enzymes. RNase H activity degrades the RNA in a DNA/RNA
hybrid and is important in nucleic acid processing in the cell,
including in DNA replication. Two DNA aptamers have
previously been in vitro selected for catalytic inhibition of human
RNase H1 [30], allowing us to specifically test for RNase H1
degradation of the fluorophore-labeled DNA/RNA hybrid.
Figure 3A shows the time evolution of the FRET ratio in several
DNA/RNA hybrid degradation assays. In the absence of any
added DNA or the presence of a negative control DNA,
degradation is rapid. When the inhibitory RNase H1 aptamers
VI-2 or V-2 were added, we observed a marked reduction in the
observed decay rate constant, indicating specific inhibition of
Figure 1. Design of the single- and double-stranded RNAs used in this study. The sequences for the RNAs are derived from the pp-luc firefly
luciferase gene and the corresponding siRNA previously reported [12,28]. The double-stranded RNAs consist of an identical central sequence and
internal FL and TMR modifications, and the flanking sequences are derived from the luciferase gene. All dsRNAs are fully Watson-Crick base paired
and contain the 2-nt 39 overhangs characteristic of siRNAs; ‘‘p’’ indicates 59 phosphate.
doi:10.1371/journal.pone.0020359.g001
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RNA hybrid. These experiments were repeated over a range of
aptamer concentrations, and a dose dependent decrease in rate
constant was observed for both aptamers (Figure 3B; VI-2: initial
rate constant v0=1.35 min
21, minimal rate constant at saturation
vmin=0.75 min
21, half-titration point VI-21/2=40 nM; V-2:
v0=1.34 min
21,v min=0.4 min
21, V-21/2=90 nM). These ob-
servations indicate that human RNAse H1 is (one of) the enzyme(s)
responsible for degrading a DNA/RNA hybrid in HeLa cell
extract.
FRET labeled 24-nucleotide dsRNA is a Dicer substrate
Interaction with Dicer is one of the earliest and most crucial
steps in RNAi, wherein larger dsRNAs are cleaved into 21-nt
fragments that Dicer then loads into the RISC complex [31–34].
To test whether our 24-nt dsRNA is an authentic substrate for
Dicer, we employed both FRET assays and gel based analysis.
First, we collected steady-state FRET time traces for our 18-, 21-,
and 24-nt dsRNAs upon addition of purified human Dicer
(Figure 4A). While the traces for the 18- and 21-nt dsRNAs hold
steady over more than 30 min incubation time, the trace of the 24-
nt dsRNA significantly increases, suggestive of an interaction with
Dicer (Figure 4A). Next, we incubated the three dsRNAs with
either human Dicer or HeLa cell extract for 200 min and analyzed
the degradation products on a denaturing FRET gel (Figure 4B).
As expected, the 24-nt dsRNA is processed by Dicer to the mature
21-nt siRNA. In HeLa cell extract, the 18-nt dsRNA exhibits a
slightly stronger degradation band at ,7 nt length than either the
21- or 24-nt dsRNAs, but with that exception the lanes are quite
similar. We only observed a weak 21-nt Dicer-derived cleavage
band in the 24-nt dsRNA lane, suggesting that processing by Dicer
under these conditions in cell extract is slow, perhaps because the
incorporation into Dicer containing protein complexes is modest
for our fluorophore-labeled dsRNAs (see also Figure 5E and
Figure 2. Monitoring the degradation of ssRNAs and dsRNAs in fetal bovine serum and HeLa S100 cytosolic cell extract. (A)
Degradation time course of the 21-nt dsRNA in 30% (v/v) serum, as monitored either in real-time by steady-state FRET (bottom) or discontinuously by
radioactive labeling and denaturing gel electrophoretic analysis of time points (top). Solid lines represent double-exponential fits to both typeso f
degradation data. In both cases the faster of the two rate constants are reported here and elsewhere and demonstrate good agreement between the
FRET and radioactive assays. (B) Denaturing radioactive gel electrophoretic analysis corresponding to the data in panel A (top). RNase T1 (‘‘T1’’) and
alkali (‘‘OH’’) ladders were run alongside varying time points of RNA degradation to identify the products. Arrows denote bands corresponding to
positions 1, 2 (from the 59 end), and PO4
32.( C) Denaturing FRET gel revealing the serum degradation patterns of the indicated RNAs as a function of
time, alongside RNase T1 (‘‘T1’’, leading to cleavage 39 of G as indicated by arrows) and alkali (‘‘OH’’) ladders as well as a TMR-only labeled color
calibration standard. The * denotes a double cut at both G13 and G3. (D) Observed degradation rate constants for the various RNAs as a function of
total serum protein concentration, quantified from FRET time traces as exemplified in panel A (bottom). (E) Degradation time course of the 21-nt
dsRNA in 30% (v/v) cell extract, as monitored either in real-time by steady-state FRET (bottom) or discontinuously by radioactive labeling and
denaturing gel electrophoretic analysis of time points (top). Solid lines represent single-exponential fits to both types of degradation data with the
respective rate constants shown, demonstrating good agreement between the FRET and radioactive assays. (F) Denaturing radioactive gel
electrophoretic analysis corresponding to the data in panel E (top). RNase T1 (‘‘T1’’) and alkali (‘‘OH’’) ladders were run alongside varying time points
of RNA degradation to identify the products. Arrows denote bands corresponding to positions 1, 2 (from the 59 end), and PO4
32.( G) Denaturing FRET
gel revealing the cell extract degradation patterns of the indicated RNAs as a function of time, alongside RNase T1 (‘‘T1’’, leading to cleavage 39 of G
as indicated by arrows) and alkali (‘‘OH’’) ladders. The * denotes a double cut at both G13 and G3. (H) Observed degradation rate constants for the
various RNAs as a function of total cell extract protein concentration, quantified from FRET time traces as exemplified in panel E (bottom). Further
details of the experiments are found in Materials and Methods.
doi:10.1371/journal.pone.0020359.g002
Protection of Double-Stranded RNAs in Cell Extract
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20359corresponding discussion below). Overall, degradation is slow over
the 200 min incubation and seems common to all dsRNAs in
HeLa cell extract, generating the diffuse, FL-only band that co-
migrates with an ,15 nt RNA fragment and is also observed in
Figure 2G.
21- and 24-nucleotide dsRNAs are protected in cell
extract
Next, we employed our steady-state FRET assay to the 18-, 21-,
and 24-nt dsRNAs and extracted the rate constants from the time
traces that were identified in Figure 2 as reflective of the RNA
degradation kinetics (the rising phase in fetal bovine serum and the
decreasing phase in HeLa extract, Figure 5). The results from
serum (Figure 5B) show that the degradation rate constants
progressively decrease with length of the dsRNA (18-nt dsRNA:
vmax=1.2 min
21, Serum1/2=4.5 mg/ml; 21-nt dsRNA:
vmax=0.47 min
21, Serum1/2=7.7 mg/ml; 24-nt dsRNA:
vmax=0.09 min
21, Serum1/2=1.7 mg/ml). This trend correlates
with the increasing distance of the fluorophores from the ends as
well as the higher thermodynamic stability of the longer duplexes
(Figure 1). By comparison, the decay rate constants observed in
cell extract appear to be an order of magnitude slower in the
FRET-based assays (filled circles in Figure 5D, left y-axis) and
even more so using 59
32P-labeled, fluorophore-labeled dsRNAs
(open circles in Figure 5D, right y-axis), measured in a less accurate,
discontinuous radioactive assay where aliquots were taken periodi-
cally and decay products analyzed by denaturing gel electrophoresis
as in Figure 2. Steady-state FRET assays revealed that the 18-nt
dsRNA is the most rapidly degraded of the three RNAs
(vmax=0.09min
21,H e L a 1/2=0.70 mg/ml). In contrast to the
serum result, the 21- and 24-nt dsRNAs exhibit the same low vmax
values,signifying that they are degraded at about the samerate in cell
e x t r a c t( 2 1 - n td s R N A :v max=0.02min
21,H e L a 1/2=0.02 mg/ml;
24-nt dsRNA: vmax=0.02min
21,H e L a 1/2=0.17 mg/ml). The
same trend was observed using the 59
32P-radiolabeled dsRNAs
(18-nt dsRNA: vmax=0.011 min
21,H e L a 1/2=0.68 mg/ml; 21-nt
dsRNA: vmax=0.0031 min
21,H e L a 1/2=0.3 mg/ml; 24-nt dsRNA:
vmax=0.0032 min
21,H e L a 1/2=0.29 mg/ml). These results suggest
that the size dependence of the protection of dsRNA from decay in
c e l le x t r a c ti sd i s t i n c tf r o mt h a ti ns e r u m .I ts h o u l db en o t e dt h a tw e
Figure 3. Inhibition of degradation of the doubly-labeled DNA/
RNA hybrid in 30% (v/v) HeLa S100 cytosolic cell extract upon
addition of DNA aptamers. (A) Steady-state FRET assays showing
attenuation of degradation by RNase H1-specific DNA aptamers VI-2
(red) and V-2 (green) at 500 nM concentration. No such attenuation is
observed in the absence of inhibitor (orange) or when 500 nM of the
negative control S1-DNA is included (blue). Solid black lines represent
single-exponential fits to the data to extract rate constants. (B) Rate
constants of DNA/RNA degradation as a function of VI-2 or V-2 aptamer
concentration. Solid lines are fits with a hyperbolic binding equation,
revealing the nanomolar binding constants for the DNA aptamers
reported in the text.
doi:10.1371/journal.pone.0020359.g003
Figure 4. Processing of doubly-labeled dsRNAs of varying
length by HeLa S100 cytosolic cell extract and purified human
Dicer. (A) Steady-state FRET time traces of 18-, 21-, and 24-nt dsRNAs as
indicated upon Dicer addition; only the 24-nt dsRNA time trace slightly
increases. (B) Denaturing FRET gel revealing the degradation patterns of
the 18-, 21-, and 24-nt dsRNAs (from left to right in each triplet of
bands) as a function of time, alongside RNase T1 (‘‘T1’’, leading to
cleavage 39 of G as indicated by arrows on the left) and alkali (‘‘OH’’)
ladders. ‘‘-’’ indicates incubation in buffer only, while the last two
triplets of bands show samples incubated in HeLa cell extract and
purified Dicer enzyme, respectively. Arrows to the right mark specific
degradation products.
doi:10.1371/journal.pone.0020359.g004
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offered ageneral,modestprotectiontotheRNAs, asmay be expected
(data not shown).
Longer fluorophore labeled RNAs are more efficiently
assembled into RISC-related complexes
To investigate the ability of the fluorophore labeled 18-, 21-,
and 24-nt dsRNAs to form protein complexes upon incubation
with HeLa cell extract we performed gel electrophoretic
mobility shift assays under non-denaturing conditions to identify
such complexes based on a modified RISC assembly assay
(Figure 5E) [35]. Characteristic RISC-related RNA:protein
complexes D (Retention factor, Rf: 0.2), C2 (0.4) and C3 (0.5)
were observed, similar to those found previously using the
unmodified 21-nt dsRNA [35]. Complex D in particular is
known to contain Dicer [35,36]. We observed that the fraction
of the fluorophore-labeled
32P-labeled RNAs incorporated into
Complex D is less than that of
32P-labeled 21-nt dsRNA devoid
of any modification, consistent with the slow processing of 24-nt
dsRNA by Dicer (Figure 4B), whereas complexes C1 and C2
a r em o r eh i g h l yp o p u l a t e d( Figure 5E). Importantly, the
fraction of 18-mer dsRNA incorporated into any of these
complexes is significantly less than those of either the 21-mer or
24-mer dsRNA, which may explain the comparatively lesser
protection of the 18-mer relative to the 21-mer and 24-mer
dsRNAs in HeLa cell extract.
Discussion
Potent and specific induction of mRNA degradation by
siRNAs is a key determinant for harnessing RNAi in reverse
genetic studies and therapeutic applications. It remains unclear,
however, just how stable siRNAsa r ei n s i d et h ec e l l .W eh a v e
previously shown the decreased nuclease sensitivity of dsRNA
compared to ssRNA in human HeLa cytosolic cell extracts
[26], and recent work has employed FRET fluctuation
spectroscopy to demonstrate this trend inside cells [23]. We
here have established real-time assays to measure degradation
profiles and kinetics for small, RNAi-related RNAs in both
blood serum and RNAi-active cytosolic cell extract. We show
that FRET-labeled RNAs interact with relevant cellular
enzymes including RNase H1 and Dicer. A DNA/RNA hybrid
is strongly protected in serum, but rapidly degraded by RNase
H1 in cell extract. 21- and 24-nt double-stranded RNAs are
equivalently protected in HeLa cell extract, but degraded
considerably faster in blood serum with their relative decay rate
constants correlating with their relative lengths. Given that the
24-nt dsRNA is a substrate of human Dicer and the 21-nt
dsRNA its product, these results suggest that RNAs that are
involved in RNAi are specifically protected in the cellular
milieu. Our observations may thus explain the relative
longevity of intracellular RNAi effects induced even by
chemically unmodified siRNAs [8].
Figure 5. Degradation kinetics of 18-, 21-, and 24-nt dsRNAs in fetal bovine serum and HeLa S100 cytosolic cell extract. (A) Steady-
state FRET time traces upon degradation of 18-, 21-, and 24-nt dsRNAs (red, green, and blue respectively) in serum. The solid black lines represent
double-exponential fits to the data, the fast rate constants of which are reported in panel B. (B) The resulting rate constants of degradation of the 18-,
21-, and 24-nt dsRNAs in serum plotted as a function of total serum protein concentration. Solid lines indicate fits with a hyperbolic binding equation.
(C) Steady-state FRET time traces upon degradation of 18-, 21-, and 24-nt dsRNAs (red, green, and blue respectively) in cell extract. The solid black
lines represent single-exponential fits to the data, the rate constant of which are reported in panel D. (D) The rate constants of degradation, derived
from steady-state FRET (solid circles, left y-axis) and radioactive assays (open circles, right y-axis) of the 18-, 21-, and 24-nt dsRNAs (red, green, and
blue respectively) in cell extract and plotted as a function of total cell extract protein concentration. Solid lines indicate fits of the FRET-derived data
with a hyperbolic binding equation. (E). Formation of complexes D, C2 and C1 after 2 h of incubation with radiolabeled 21-nt dsRNA with no
modification (lane 1), 18-nt dsRNA (lane 2), 21-nt dsRNA (lane 3) and 24-nt dsRNA (lane 4) in HeLa cytosolic extract. Lanes 5–8 represent the respective
negative controls in the absence of cell extract with the dsRNAs in the same order from left to right. Normalized fractions in percent are indicated for
each boxed band; * indicates an unknown complex.
doi:10.1371/journal.pone.0020359.g005
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corresponding ssRNA in both HeLa cell extract and blood serum
(Figure 2). These results are consistent with the relative stiffness of
the RNA duplex, stabilizing the phosphodiester and ribose torsion
angles in conformations less amenable to the in-line attack
conformation needed by ribonucleases such as the RNase A-like
enzymes dominant in serum [29,37]. Hybridization to a DNA
further stabilizes the RNA component in blood serum, perhaps
due to perturbation of the A-form helical structure or lack of 29-
OH functionality on an entire strand of the duplex. By contrast, in
cell extract the DNA/RNA hybrid is rapidly degraded by RNase
H1, as shown by enzyme-specific inhibition by two in vitro selected
DNA aptamers [30] (Figure 3). In human cells, a second,
disparate, multi-subunit enzyme, termed RNase H2, has been
characterized that degrades DNA/RNA hybrids [38]. This may
be the enzyme that causes the residual DNA/RNA decay upon
maximal inhibition of RNase H1 (Figure 3).
The size range of the dsRNAs we tested for their stability in
serum and cell extract was chosen to bracket the specific 21-nt size
of siRNAs in human cells. dsRNAs larger than ,21 nt are cleaved
by human Dicer into siRNAs during the initial step of RNAi, as
observed here for the 24-nt dsRNA, followed by incorporation
into the RISC-loading complex (RLC), comprising the proteins
Dicer, Ago2, and TRBP [33,34]. Since cellular delivery of 21-nt
siRNAs induces RNAi, albeit not as effectively as does delivery of
Dicer substrates [27], both types of dsRNAs must be interacting
with the components of the RNAi machinery, in contrast to
shorter dsRNAs. The similar protection of 21- and 24-nt dsRNAs
in our assays relative to the corresponding 18-nt dsRNA (Figure 5)
is consistent with these findings. In addition, the fraction of 18-mer
dsRNA incorporated into RISC-related protein complexes is
significantly less than those of either the 21-mer or 24-mer
dsRNAs (Figure 5E). This result suggests that the comparatively
faster degradation rate of the 18-mer versus the 21-mer and 24-
mer dsRNAs may be linked to the existence of protective
RNA:protein complexes in HeLa cell extract preferably for the
longer dsRNAs. By contrast, the efficiency of dsRNA degradation
in blood serum monotonically decreases with increasing RNA size,
that is, with distance of the FRET fluorophores from the ends and
overall thermodynamic stability of the duplex (Figure 5). These
observations are in line with the known properties of RNase A,
where the limiting step of enzyme action on dsRNA substrates is
invasion of the duplex to access an in-line attack conformation and
cleave the RNA backbone [37].
In summary, our results are consistent with established steps in
the RNAi pathway where dsRNAs of ,21 nucleotides per strand
are bound by the RLC or other RNAi components and remain
largely hidden from nucleolytic decay either as the base-paired
siRNA duplex or as the single guide strand processed into active
RISC. The real-time in vitro FRET assays established here open up
the possibility for future high-throughput screening of the
nucleolytic stability of additional chemically modified RNAi
effector molecules.
Materials and Methods
Nucleic acid synthesis and labeling
All RNAs were synthesized by the HHMI Biopolymer/Keck
Foundation Biotechnology Resource Laboratory at the Yale
University School of Medicine, deprotected, TMR labeled (as
necessary), and purified as previously described [39–41]. More
specifically, the guide strand was labeled during synthesis with
Fluorescein dT and Amino-Modifier C6 dT in the positions
indicated in Figure 1; the amino-modifier was subsequently
coupled to TMR succinimidyl ester (Invitrogen), the RNA purified
away from free dye by C18-reversed phase HPLC, and its purify
checked by denaturing polyacrylamide gel electrophoresis [39–
41]. Sequences are derived from the firefly luciferase gene and
have been shown to be effective in RNAi-mediated target cleavage
[12,28]. All RNAs were purchased with a 59 phosphate group,
except for a second fluorophore-labeled 21-nt guide strand with a
59 OH used for radiolabeling. The DNA oligonucleotides used in
our studies (Sequence = VI-2, V-2, and S1-DNA) [30] were
synthesized by Invitrogen and had the following sequences: VI-2,
CGGTCGCTCCGTGTGGCTTGGGTTGGGTGTGGCAGT-
GAC; V-2, GCTGGTCTCTGCGGGTTGTTGCGCCGCG-
GCACCCTTGGCA; S1-DNA, CGTACGCGGAATACTTT-
GAAA.
Steady-state FRET assays of RNA degradation
A final concentration of 50 nM FL and TMR doubly-labeled
RNAs was annealed either alone (single-stranded RNA) or with
100 nM (final concentration, in excess for saturation) of an
appropriate DNA or RNA complement by heating to 70uC for
2 min and cooling to room temperature over 10 min in a standard
buffer of 50 mM Tris-HOAc, pH 7.4, 80 mM KCl, 20 mM
NaCl, and 1 mM MgCl2 (chosen to mimic physiologic conditions).
After the 10-min cooling period at room temperature, RNA
solutions were incubated in a circulating water bath at 37uC for
5 min before the samples were added to a fluorometer cuvette,
also controlled at 37uC. After the initiation of collection of donor
(F520) and acceptor fluorescence emission signal (F585) as described
previously [41], a baseline measurement was recorded for
approximately 50–100 seconds before a fraction of either HeLa
S100 cytoplasmic cell extract (a gift from Danny Reinberg,
Department of Biochemistry, Rutgers University, prepared and
dialyzed following published protocols [42]), fetal bovine serum
(Gibco), or purified Dicer (Stratagene, 2 Units) was added and the
resulting signal evolution recorded. The FRET ratio Q (F585/
(F585+F520)) was plotted over time t and fit where appropriate with
either the single- or double-exponential form of the following
expression to extract the observed rate constants kobs (please note
that in case of a decreasing data curve the pre-exponential factor A
is positive, otherwise negative):
y~y0zA1e
{kobs,1tzA2e
{kobs,2t ðEq:1Þ
These assays were carried out over a range of 0–30% (v/v)
HeLa cell extract and serum volume additions, equivalent to
0–2.5 mg/ml total HeLa protein (concentration measured by
Bradford assay) and 0–11.1 mg/ml total serum protein (concen-
tration provided by Gibco). The observed rate constants were
plotted as a function of total protein content and fit with the
following hyperbolic binding equation that does not assume
cooperativity:
y~
vmax½protein 
protein1=2z½protein 
ðEq:2Þ
In this equation, vmax is the maximal rate constant at saturation,
and protein1/2 is the half-titration point.
RNase H1 inhibition assays
Fluorometer assays to monitor RNase H1 inhibition by DNA
aptamers VI-2 and V-2 [30] were conducted identically to the
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The HeLa cell extract used in these assays was pre-incubated
with a defined concentration of the pre-annealed DNA aptamer
or the negative control DNA S1 for 30 min at 37uCb e f o r e
mixing with the DNA/RNA hybrid in the fluorometer. In
addition, the DNA/RNA hybrid was prepared in the presence of
the respective aptamer or control DNA at a concentration equal
to that in the HeLa cell extract. Again, the FRET Ratio Q for
each trace was extracted and fit with a single-exponential
expression as above, and the observed rate constants were
plotted as a function of aptamer concentration and fit with the
following hyperbolic binding equation below where no coopera-
tivity was assumed:
y~v0{
(v0{vmin)½aptamer 
aptamer1=2z½aptamer 
ðEq:3Þ
Here, vmin is the minimal rate constant reached at saturation and
aptamer1/2 is the half-titration point.
FRET-monitored gel electrophoretic analysis of RNA
fragments
Denaturing gel electrophoresis was paired with FRET
detection of the RNA to gain qualitative insight into the
processing of the labeled RNAs by Dicer, cell extract, and
serum. The doubly-labeled RNA strand was prepared at 500 nM
final concentration in standard buffer, the complementary RNA
or DNA as necessary added to 1 mM concentration and annealed
as described above. After cooling, Dicer, cell extract, or serum
was added as indicated and the samples were incubated at 37uC
until the reactions were stopped by mixing with a final
concentration of 10% (v/v) Contrad 70 at pH 9.3 (Decon Labs)
as previously described [26]. For the samples of the FRET gel in
Figure 2C, serum was added to a final total protein
concentration of 11.1 mg/ml for the DNA/RNA hybrid and
dsRNA, but only 0.93 mg/ml for the ssRNA. Time points for
these reactions were as follows: ssRNA, 1, 5, and 10 min; DNA/
RNA hybrid and dsRNA, 0.5, 1 and 2.5 h. For the samples of the
FRET gel in Figure 2G, HeLa cell extract was added
throughout to a final total protein concentration of 2.49 mg/ml
and time points were taken at 5, 10, and 20 min for the ssRNA
and the DNA/RNA hybrid, while time points of 5, 20, and
60 min were taken for the dsRNA. The samples for the FRET gel
in Figure 4B were prepared by exposing each of the 18, 21, and
24-nt double-stranded RNAs to Dicer enzyme (1 unit), HeLa cell
extract (2.49 mg/ml), or buffer alone for 200 min (3.3 h). The
buffer for the HeLa and buffer only reactions was composed of
our standard buffer supplemented with 10 mM DTT, and the
Dicer reactions contained the buffer supplied and recommended
by the manufacturer whose final composition was 20 mM Tris-
HCl, pH 8.0, 150 mM NaCl, and 2.5 mM MgCl2. The T1 and
OH lanes in the gels refer to reference ladders using RNase T1
and alkali (OH
2) digestion, respectively, prepared as described
[12] except that no carrier tRNA was added to the RNase T1
digest. For all reactions, 10 pmol/lane of labeled RNA was mixed
with loading buffer for a final concentration of 16TBE, 0.025%
(w/v) bromophenol blue, and 40% (v/v) formamide, and the
products were separated on a denaturing, 8 M urea, 20% (w/v)
polyacrylamide gel. Fluorescence detection of the RNA was
accomplished using a FluorImager SI fluorescence scanner with
ImageQuant software (Molecular Dynamics) as previously
described [43,44].
Radioactivity-monitored gel electrophoretic analysis of
RNA fragments and RISC-related RNA:protein complexes
The 21-nt non-phosphorylated, doubly-fluorophore labeled
RNA was 59-
32P labeled with T4 polynucleotide kinase (PNK)
and c-
32P-ATP, mixed with loading buffer to give a final
concentration of 16TBE, 0.025% (w/v) bromophenol blue, and
40% (v/v) formamide, and gel purified on a denaturing, 8 M urea,
20% (w/v) polyacrylamide gel. The radiolabeled full-length RNA
was excised from the gel, diffusion eluted into 1 mM EDTA
overnight, and ethanol precipitated. The dried RNA was dissolved
in water.
59-
32P labeled RNA (50,000 cpm/lane) was mixed with
50 nM non-radiolabeled, but 59 phosphorylated, doubly-fluor-
ophore labeled RNA and 100 nM of the complementary 21-nt
RNA strand, and annealed as described above in standard
buffer. Degradation was initiated by the addition of a final total
protein concentration of 2.49 mg/ml cell extract or 11.1 mg/ml
serum at 37uC. For the analysis in Figure 5D, the assays were
carried out over a range of 0–30% ( v / v )H e L ac e l le x t r a c t .T i m e
points were taken after 2, 5, 10, 20, 40, and 80 min for the cell
extract sample and 5, 10, 20, 40, 80, 120, and 180 min for the
serum sample. For the analysis in Figure 5D,t i m ep o i n t sw e r e
instead taken 2, 5, 10, 20 and 40 min after the addition of cell
extract. All time points were quenched by mixing with a final
concentration of 10% (v/v) Contrad 70 at pH 9.3 (Decon Labs)
[26]. Loading buffer was added to a final concentration of
16TBE, 0.025% (w/v) bromophenol blue, 0.025% (w/v) xylene
cyanol, and 40% (v/v) formamide, and the degradation
products separated on a denaturing, 8 M urea, 20% (w/v)
polyacrylamide gel. Individual bands were identified by
comparison with sequencing ladders from partial digestion with
G-specific RNase T1 and alkali as described [45], quantified
and normalized to the sum of all bands in a lane using a
PhosphorImager Storm 840 with Image Quant software
(Molecular Dynamics). Any error bars are derived from three
independent determinations.
For the radioactive dsRNA degradation data in Figure 5D the
normalized ratio of intact dsRNA over the sum of all bands in a
lane was plotted over time t and fitted with a simple linear
regression line to estimate the observed rate constant kobs:
y~y0{kobs.t ðEq:4Þ
These assays were carried out over a range of 0–30% (v/v)
added HeLa cell extract, equivalent to 0–2.5 mg/ml total HeLa
protein (concentration measured by Bradford assay). The
observed rate constants were plotted as a function of total
protein content and fitted as above with hyperbolic binding
equation 2.
The gel electrophoretic mobility shift assays of RISC-related
RNA:protein complexes were initiated by the addition of a final
total protein concentration of 2.49 mg/ml cell extract to the
annealed 59-
32P labeled RNA in standard buffer at 4uC. After
2 h incubation the reaction was stopped by mixing with non-
denaturing loading buffer to a final concentration of 16TBE,
0.025% (w/v) bromophenol blue and 0.025% (w/v) xylene
cyanol and the RNA-associated complexes were separated by
non-denaturing 4% (w/v) polyacrylamide gel electrophoresis at
4
oC, quantified and normalized to the sum of all bands in a
lane using a Typhoon 9410 Variable Mode Imager with Image
Quant software (GE Healthcare), essentially as described [35].
Three independent analyses gave similar results.
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Figure S1 FRET ratio time trace upon incubating
doubly fluorophore labeled 21-nt dsRNA with either
serum (red) or 2 ng/ml of purified RNase A (black). The
real-time FRET traces for each of these conditions reveal that both
serum and the purified nuclease manifest a significant initial
increase in FRET ratio.
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